xmp-biotech.org
XMP-Biotech
http://xmp-biotech.org/liste-conferences.html
Les conférences XMP-Biotech depuis 2003. Depuis plus de 10 ans, XMP-Biotech, groupe des anciens élèves de l' École Polytechnique. Et des Mines de Paris. Actifs dans les entreprises des sciences du vivant, organise des conférences sur des thématiques très variées. Nous espérons avoir la chance de vous croiser à l'un de nos prochains événements. 23 novembre 2015, Colloque XMP-Biotech. La Révolution du Big Data et du Numérique dans le Monde de la Santé". Sponsorisé par Pierre Fabre. CEREGE), Eric Gaffet.
innovaction.fr
Innovaction - Valorisation et management de l'innovation
http://www.innovaction.fr/reference.php
Pharma - Santé - Biotechnologies. STIC (Sciences et Technologies de l'Ingénieur et de la Communication). Depuis 1996, Innovaction a contribué au montage de plus de 30 entreprises technologiques. Nous travaillons. D'abord dans le secteur des biotechnologies, mais aussi dans celui des STIC (Sciences et Technologies de. L'Ingénieur et de la Communication). Ce positionnement nous permet ainsi de mener des mission dans les. Domaines de l'informatique l'instrumentation médicale (ex : imagerie). Biotechnologie ...
px-therapeutics.com
PX'Therapeutics References
http://www.px-therapeutics.com/px_references.php
PX'Therapeutics has been working with over 200 biopharmaceutical companies and academic research. Centres through service based contracts or research collaborations. European Synchrotron Research Facility. University of New South Wales. Preclinical activity of OM-RCA-01, a humanized antiFGFR1 antibody, in renal cell carcinoma (RCC). Expression of a cGMP Compatible Lucilia sericata Insect Serine Proteinase Debridement Enzyme. List of partners and collaborators. Ministry of Defence, France).
inserm-transfert.fr
Spin-offs - Inserm Transfert
http://inserm-transfert.fr/en/achievements/spinoffs.html
Maturation, Protecting and IP. Partnering: R&D, Public health. Some remarkable spin-offs backed by Inserm's technology. More than 120 start-ups companies have been created over the past 35 years. Cancer and inflammatory diseases. Biomarkers for inflammatory chronic diseases. Cancer and chronic infectious diseases. All therapy for chronic inflammatory diseases. Maturation, Protecting and IP. Partnering: R&D, Public health. Paris Biopark - 7 rue Watt - 75013 PARIS. 33 (0)1 55 03 01 00. 33 (0)1 55 03 01 60.
drugabilis.com
Drugabilis - Drugability for biotech and pharmaceutical research
http://www.drugabilis.com/siteweb-spe-about-us.php?id=1945
Low soluble compounds parenteral formulation. Bull; • •. For 2014, 2015 and 2016. The " Agrément Crédit Impôt Recherche. From the French Ministry of Research. Drugabilis has been accredited since 2006. Bull; • •. Drugabilis is a funding member of the French Association AFSSI. Sciences de la Vie. Bull; • •. Begining of 2006,. Receives confirmation of its Young Innovative Company status. From the French authorities. Bull; • •. Is recognised and supported by Genopole. Bull; • •. Bull; • •.
andrecontrelasla.be
Nouveau site Internet d'information à destination des médecins et des malades souffrant de la Sclérose Latérale Amyotrophique (SLA) - André contre la S.L.A
http://www.andrecontrelasla.be/Nouveau-site-Internet-d.html
André contre la S.L.A. Rechercher dans le site. La recherche S.L.A. Nouveau site Internet d’information à destination des médecins et des malades souffrant de la Sclérose Latérale Amyotrophique (SLA). Jeudi 4 mars 2010. Popularité : 1%. Le consortium MitoTarget lance un nouveau site Internet d’information à destination des médecins et des malades souffrant de la Sclérose Latérale Amyotrophique (SLA), maladie orpheline également connue sous le nom de maladie de Charcot. Le MitoTarget est un consortium fin...
neuroservice.com
Olesoxime, a first hope for Spinal Muscular Atrophy (SMA) patients
http://www.neuroservice.com/en/olesoxime-a-first-hope-for-spinal-muscular-atrophy-sma-patients-by-thierry-bordet
Olesoxime, a first hope for Spinal Muscular Atrophy (SMA) patients. Olesoxime, a first hope for Spinal Muscular Atrophy (SMA) patients. Has more than 15 years of experience leading drug discovery. Efforts from preclinical research to proof-of-concept across biotech and academic settings. At Trophos. Thierry led various drug discovery programs for motor neuron disorders which culminated in the identification of Olesoxime. The first treatment for Spinal Muscular Atrophies (SMA). When Roche, one of the worl...
pxpharma.com
PX'Therapeutics References
http://www.pxpharma.com/px_references.php
PX'Therapeutics has been working with over 200 biopharmaceutical companies and academic research. Centres through service based contracts or research collaborations. European Synchrotron Research Facility. University of New South Wales. Preclinical activity of OM-RCA-01, a humanized antiFGFR1 antibody, in renal cell carcinoma (RCC). Expression of a cGMP Compatible Lucilia sericata Insect Serine Proteinase Debridement Enzyme. List of partners and collaborators. Ministry of Defence, France).
smareachuk.com
Clinical Trials in SMA - SMA REACH UK
http://www.smareachuk.com/clinical-trials-in-sma.html
Clinical Trials in SMA. TREAT-NMD: Trials in SMA. Information on the Trophos study. Trohphos Study: A Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients. Olesoxime is an advanced drug candidate for SMA having completed a pivotal phase II trial in 2013. Roche will initiate the manufacturing of olesoxime and associated regulatory activities to allow an open-label ex...